Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers.

By W. Samowitz, C. Sweeney, Jennifer S. Herrick, H. Albertsen, T. Levin, M. Murtaugh, R. Wolff, M. Slattery. Cancer Research, 2005

787 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/c2c0d8c90898c3cf250413c057307797eb8b3004

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Edward L. Giovannucci
2. Walter Kolch
3. J. Jass

In Pathology and Forensic Medicine

1. Edward L. Giovannucci
2. J. Jass

Citations in the corpus

• Classification of colorectal cancer based on correlation of clinical, morphological and molecular features (2007, background): “84).(61) Among subjects with MSI-H CRC, BRAF mutation was a negative predictor for a positive family history.”
• Impact of BRAF Mutation and Microsatellite Instability on the Pattern of Metastatic Spread and Prognosis in Metastatic Colorectal Cancer (2011, result): “We observed significant associations between BRAF mutant CRC and rightsided primaries, MSI, and poorer overall survival, all consistent with previous reports.(3,18,20) The significantly lower rate of metastasectomy in BRAF mutant tumors is not unexpected, given the poorer survival observed in these ”
• CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer (2008, result): “[22,27] Our findings of good prognosis in CIMP-high tumors appear to differ from the data in the previous studies.”
• MAP kinase signalling pathways in cancer (2007, background): “Although it has no bearing on the good prognosis of MSI-positive tumours, it is associated with poor prognosis in microsatellite-stable cancers (Samowitz et al., 2005).”
• Colorectal carcinoma: Pathologic aspects. (2012, background): “BRAFmutated MSI-H tumor and BRAF wild-type MSS tumor are intermediate in terms of prognosis (132,133).”
• Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies (2014, neutral): “BRAF has a negative prognostic impact, although this may be restricted to patients with proficient MMR (pMMR) tumors (15, 16).”